StoxOnesource Specialty Pharma vs Rainbow Childrens Medicare: share price & financials comparison
NSE: ONESOURCE vs RAINBOW · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Onesource Specialty Pharma vs Rainbow Childrens Medicare at a glance
Onesource Specialty Pharma (ONESOURCE) has a market capitalisation of ₹18,463 Cr, against ₹12,914 Cr for Rainbow Childrens Medicare (RAINBOW). Over the past year Rainbow Childrens Medicare has returned -8.6%, compared with -12.2% for Onesource Specialty Pharma. Rainbow Childrens Medicare earns a higher return on equity (17.0% vs -0.0%). Onesource Specialty Pharma comes out ahead on valuation, growth, momentum and technicals. Rainbow Childrens Medicare comes out ahead on size and profitability. Across the scored metrics below, Onesource Specialty Pharma leads on 6 and Rainbow Childrens Medicare on 5. On StoxGud's 10-point checklist, Onesource Specialty Pharma scores 4/10 and Rainbow Childrens Medicare scores 5/10.
| Metric | Onesource Specialty Pharma | Rainbow Childrens Medicare |
|---|---|---|
| Size | ||
| Market cap | ₹18,463 Cr | ₹12,914 Cr |
| Revenue (latest FY) | ₹1,422 Cr | ₹1,703 Cr |
| Net profit (latest FY) | ₹-74 Cr | ₹278 Cr |
| Valuation | ||
| P/E | — | 44.2 |
| P/B | 3.12 | 7.53 |
| Dividend yield | — | 0.24% |
| Profitability | ||
| Return on equity | 0.0% | 17.0% |
| Net profit margin | -0.1% | 15.2% |
| Operating margin | 23.5% | 31.0% |
| Growth | ||
| Revenue growth (YoY) | +37.4% | +23.2% |
| Net profit growth (YoY) | +687.0% | +9.1% |
| Revenue CAGR (multi-year) | — | +15.0% |
| Financial health | ||
| Debt to equity | 0.25 | 0.00 |
| Momentum | ||
| 1-month return | +10.3% | +4.5% |
| 1-year return | -12.2% | -8.6% |
| 3-year CAGR | — | +7.7% |
| Distance from 52W high | -13.8% | -20.5% |
| Technicals | ||
| RSI (14) | 82 | 71 |
| Price vs 200-day avg | +4.0% | -3.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Onesource Specialty Pharma | Rainbow Childrens Medicare |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 4/10 | 5/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Onesource Specialty Pharma or Rainbow Childrens Medicare?
Onesource Specialty Pharma has a market cap of ₹18,463 Cr and Rainbow Childrens Medicare has a market cap of ₹12,914 Cr as of 13 Nov 2026.
Which gave better returns in the last year, Onesource Specialty Pharma or Rainbow Childrens Medicare?
Rainbow Childrens Medicare did better: Onesource Specialty Pharma returned -12.2% and Rainbow Childrens Medicare returned -8.6% over one year.
What is the difference between Onesource Specialty Pharma and Rainbow Childrens Medicare?
Both are NSE-listed companies in Healthcare. Onesource Specialty Pharma is about 1.4 times the size of Rainbow Childrens Medicare by market cap. In the latest financial year Onesource Specialty Pharma reported revenue of ₹1,422 Cr and Rainbow Childrens Medicare ₹1,703 Cr. Operating margin is 23.5% for Onesource Specialty Pharma and 31.0% for Rainbow Childrens Medicare. Debt to equity is 0.25 for Onesource Specialty Pharma and 0.00 for Rainbow Childrens Medicare.
Which is better, Onesource Specialty Pharma or Rainbow Childrens Medicare?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Onesource Specialty Pharma leads on 6 and Rainbow Childrens Medicare on 5. Onesource Specialty Pharma is ahead on valuation, growth, momentum and technicals. Rainbow Childrens Medicare is ahead on size and profitability. On StoxGud's rules-based checklist Onesource Specialty Pharma scores 4/10 and Rainbow Childrens Medicare scores 5/10. This is information, not advice: consult a SEBI-registered adviser before investing.